[Federal Register Volume 65, Number 10 (Friday, January 14, 2000)]
[Notices]
[Page 2416]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-889]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Peripheral and Central Nervous System Drugs Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of a meeting of the Peripheral and Central 
Nervous System Drugs Advisory Committee. This meeting was announced in 
the Federal Register of December 27, 1999 (64 FR 72355). The amendment 
is being made to cancel the entire session on January 27, 2000. This 
meeting will be open to the public. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Sandra L. Titus, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) 
Rockville, MD 20857, 301-827-7001, or e-mail [email protected], or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area) code 12543. Please call the Information 
Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 27, 1999 
(64 FR 72355), FDA announced that a meeting of the Peripheral and 
Central Nervous System Drugs Advisory Committee would be held on 
January 27 and 28, 2000. On page 72355, beginning in the first column, 
the Date and Time, Agenda, and Procedure portions of this meeting are 
amended to read as follows:
    Date and Time: The meeting will be held January 28 from 8 a.m. to 5 
p.m.
    Location: Hilton, 620 Perry Ave., Gaithersburg, MD.
     Agenda: On January 28, the committee will consider the safety and 
efficacy of new drug NDA 21-120, Novantrone , (mitoxantrone, 
Immunex Corporation) proposed to treat secondary progressive multiple 
sclerosis, including progressive relapsing disease.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by January 20, 
2000. Oral presentations from the public will be scheduled between 
approximately 1 p.m. and 2 p.m. on both days. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before January 20, 2000, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
     Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 7, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-889 Filed 1-13-00; 8:45 am]
BILLING CODE 4160-01-F